C560Rβ3 caused platelet integrin αIIbβ3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1163-1171

  Fang, J ^a,b,c   Nurden, P ^d,e   North, P ^a   Nurden, A T ^d   Du, L M ^a,b,c   Valentin, N ^f   Wilcox, D A ^a,b,c,g  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

^c Midwest Athletes Against Childhood Cancer Inc   (United States)

^d Ctr Geriatrie Ctr Hosp Univ B   (France)

^e TIMONE HOSPITAL   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Glanzmann thrombasthenia; Hematopoietic stem cells; Integrin IIb 3; Lentivirus gene transfer; Megakaryocytes; Platelets

Indexed keywords

FIBRINOGEN; HEMOSIDERIN; INTEGRIN; PADGEM PROTEIN;

ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE SEVERITY; EXTRAMEDULLARY HEMATOPOIESIS; GLANZMANN DISEASE; IN VITRO STUDY; IN VIVO STUDY; MEGAKARYOCYTE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN;

GLANZMANN THROMBASTHENIA; HEMATOPOIETIC STEM CELLS; INTEGRIN ΑIIBΒ3; LENTIVIRUS GENE TRANSFER; MEGAKARYOCYTES; PLATELETS;

ANIMALS; BLOOD PLATELETS; BONE MARROW CELLS; FIBRINOGEN; HEMORRHAGE; HUMANS; INTEGRIN BETA3; LENTIVIRUS; MEGAKARYOCYTES; MICE; MUTATION; P-SELECTIN; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; PROTEIN CONFORMATION; SYNDROME; THROMBASTHENIA; THROMBOSIS;

EID: 84883256631     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12209     Document Type: Article

References (27)

1. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5996-6005.
2. Hardisty R, Pidard D, Cox A, Nokes T, Legrand C, Bouillot C, Pannocchia A, Heilmann E, Hourdille P, Bellucci S, Nurden A. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood 1992; 80: 696-708.
3. Peyruchaud O, Nurden AT, Milet S, Macchi L, Pannochia A, Bray PF, Kieffer N, Bourre F. R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 1998; 92: 4178-87.
4. Ghevaert C, Salsmann A, Watkins NA, Schaffner-Reckinger E, Rankin A, Garner SF, Stephens J, Smith GA, Debili N, Vainchenker W, de Groot PG, Huntington JA, Laffan M, Kieffer N, Ouwehand WH. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 2008; 111: 3407-14.
5. Kunishima S, Kashiwagi H, Otsu M, Takayama N, Eto K, Onodera M, Miyajima Y, Takamatsu Y, Suzumiya J, Matsubara K, Tomiyama Y, Saito H. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the {alpha}IIb{beta}3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011; 117: 5479-84.
6. Ruan J, Schmugge M, Clemetson KJ, Cazes E, Combrie R, Bourre F, Nurden AT. Homozygous Cys542->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. Br J Haematol 1999; 105: 523-31.
7. Mor-Cohen R, Rosenberg N, Peretz H, Landau M, Coller BS, Awidi A, Seligsohn U. Disulfide bond disruption by a beta 3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active alpha IIb beta 3. Thromb Haemost 2007; 98: 1257-65.
8. Ruiz C, Liu CY, Sun QH, Sigaud-Fiks M, Fressinaud E, Muller JY, Nurden P, Nurden AT, Newman PJ, Valentin N. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001; 98: 2432-41.
9. Ambo H, Kamata T, Handa M, Taki M, Kuwajima M, Kawai Y, Oda A, Murata M, Takada Y, Watanabe K, Ikeda Y. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun 1998; 251: 763-8.
10. Mor-Cohen R, Rosenberg N, Landau M, Lahav J, Seligsohn U. Specific cysteines in beta3 are involved in disulfide bond exchange-dependent and -independent activation of alphaIIbbeta3. J Biol Chem 2008; 283: 19235-44.
11. Morgan EA, Schneider JG, Baroni TE, Uluckan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J 2010; 24: 1117-27.
12. Mor-Cohen R, Rosenberg N, Einav Y, Zelzion E, Landau M, Mansour W, Averbukh Y, Seligsohn U. Unique disulfide bonds in epidermal growth factor (EGF) domains of beta3 affect structure and function of alphaIIbbeta3 and alphavbeta3 integrins in different manner. J Biol Chem 2012; 287: 8879-91.
13. Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA. Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia. Blood 2005; 106: 2671-9.
14. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000; 84: 1095-102.
15. Frei AC, Guo Y, Jones DW, Pritchard KA Jr, Fagan KA, Hogg N, Wandersee NJ. Vascular dysfunction in a murine model of severe hemolysis. Blood 2008; 112: 398-405.
16. Wandersee NJ, Lee JC, Deveau SA, Barker JE. Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells. Blood 2001; 97: 3972-5.
17. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost 2003; 1: 2477-89.
18. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-38.
19. Parmley RT, Kim TH, Austin RL, Alvarado CS, Ragab AH. Emperipolesis of neutrophils by dysmorphic megakaryocytes. Am J Hematol 1982; 13: 303-11.
20. de Pasquale A, Paterlini P, Quaglino D. Emperipolesis of granulocytes within megakaryocytes. Br J Haematol 1985; 60: 384-6.
21. Hsiao G, Yen MH, Lee YM, Sheu JR. Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo. Br J Haematol 2002; 117: 699-704.
22. Calvete JJ, Jurgens M, Marcinkiewicz C, Romero A, Schrader M, Niewiarowski S. Disulphide-bond pattern and molecular modelling of the dimeric disintegrin EMF-10, a potent and selective integrin alpha5beta1 antagonist from Eristocophis macmahoni venom. Biochem J 2000; 345(Pt 3): 573-81.
23. Kamata T, Ambo H, Puzon-McLaughlin W, Tieu KK, Handa M, Ikeda Y, Takada Y. Critical cysteine residues for regulation of integrin alphaIIbbeta3 are clustered in the epidermal growth factor domains of the beta3 subunit. Biochem J 2004; 378: 1079-82.
24. Milet-Marsal S, Breillat C, Peyruchaud O, Nurden P, Combrie R, Nurden A, Bourre F. Two different beta3 cysteine substitutions alter alphaIIb beta3 maturation and result in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 104-10.
25. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011; 9(Suppl. 1): 76-91.
26. Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol 2002; 9: 282-7.
27. Fang J, Jensen ES, Boudreaux MK, Du LM, Hawkins TB, Koukouritaki SB, Cornetta K, Wilcox DA. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci USA 2011; 108: 9583-8.